Glaucoma is the leading cause of preventable blindness in American adults. However,
if elevated intraocular pressure
(IOP) is caught early and managed with medication—like LUMIGAN®—many
people may reduce their risk of vision loss.
Glaucoma is associated with several risk factors including elevated intraocular
pressure inside the eye, called IOP. Many people may not know they are at risk for
glaucoma because elevated IOP often has no symptoms.
Risk factors for glaucoma
If you have any of the risk factors below for glaucoma, you should have your eyes
checked regularly or as instructed by your doctor. While glaucoma is a lifelong
condition, lowering IOP with daily treatment can help reduce your risk of vision
loss.
The effects of glaucoma
Sometimes, vision loss due to glaucoma is depicted as "tunnel vision." But that's
not truly what people with glaucoma experience.
Visual field loss does often
start with the peripheral vision. Many people with glaucoma don't realize this because
they don't actually "see" dark areas—they just have a narrower visual field and
“see” less of their surroundings.
If left untreated, elevated IOP can lead to a loss of peripheral vision
Even a slight loss of peripheral vision can make it more difficult to perform daily
activities. Don't assume that you know how well you are seeing. Get the facts, and
if you're prescribed medication to treat risk factors for glaucoma, stick to it
every day.
LUMIGAN® 0.01% and 0.03% (bimatoprost ophthalmic solution) is used
for the treatment of high eye pressure, also called intraocular pressure (IOP),
in people with open-angle glaucoma or ocular hypertension.
Important Safety Information
LUMIGAN® 0.01% and 0.03% (bimatoprost ophthalmic solution) has been
reported to cause darkening (pigmentation) of eye color, eyelid skin, and eyelashes
as well as increased growth of eyelashes. Pigmentation changes can increase as long
as LUMIGAN® 0.01% and 0.03% is used. After stopping LUMIGAN®
0.01% and 0.03%, darkening of eye color is likely to be permanent, while darkening
of the eyelid skin and eyelash changes may be reversible. The effects of increased
darkening beyond 5 years are not known.
When only one eye is treated, there is a possibility of eyelash changes in the eye
treated with LUMIGAN® 0.01% and 0.03%. These changes may result in
differences between the eyes in eyelash length, thickness, darkness, number of eyelashes,
and/or direction of eyelash growth. These changes are usually reversible upon stopping
LUMIGAN® 0.01% and 0.03% therapy.
Avoid allowing the tip of the dispensing bottle to touch the eye, anything around
the eye, fingers, or any other surface in order to avoid contamination by common
bacteria known to cause eye infections. Serious damage to the eye and loss of vision
may result from using contaminated solutions.
If you have eye surgery or develop any eye reactions (such as trauma or infection),
immediately consult with your physician about continuing the use of LUMIGAN®
0.01% and 0.03%.
If you wear contact lenses, remove them before using LUMIGAN® 0.01%
and 0.03%. Then wait 15 minutes after using LUMIGAN® 0.01% and 0.03%
before you put your contacts back into your eyes.
The most common side effects are eye redness, growth of eyelashes, and itchy eyes.
Click here
for full prescribing information.